Korean biotech developing autologous stem-cell therapies, including a knee-osteoarthritis treatment, made from patients' own fat tissue.
Korean biotech developing autologous stem-cell therapies, including a knee-osteoarthritis treatment, made from patients' own fat tissue.
Moat: narrow (IP / patents, regulatory licence). Patented autologous stem-cell process, though facing efficacy/regulatory skepticism.
Headquarters: Seoul, South Korea · Founded: 2002 · Employees: 83
Size NATURECELL (007390.KS) is a South Korea Consumer Staples company (Beverages: Non-Alcoholic) with a market value of $1.03B, the 234th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩21,450 on 18 Nov 2026.
Performance Over six months the shares gained 17.5%, against -2.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 14.5% over the last twelve months (peer median +2.7%); the operating margin is -53.5% (peer median 8.2%).
Valuation It trades at 72.8× enterprise value to sales against a peer median of 1.5× (most expensive of 21).
Capital Return on invested capital runs 20.8 points below its cost of capital (8.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩18.9B | ₩20.7B | ₩32.3B | ₩19.4B | ₩21.3B |
| Revenue growth | — | -36% | +67% | -9% | — |
| Gross profit | ₩8.22B | ₩8.15B | ₩15.5B | ₩7.05B | ₩8.41B |
| EBITDA | -₩8.05B | -₩1.82B | ₩2.48B | -₩8.82B | -₩8.10B |
| Net income | -₩10.7B | -₩2.84B | ₩1.23B | -₩11.7B | -₩10.3B |
| Free cash flow | -₩31.4B | -₩16.4B | -₩1.59B | -₩8.25B | -₩18.7B |
| Capital expenditure | ₩17.1B | ₩16.6B | ₩3.12B | ₩6.12B | ₩3.80B |
| Total debt | ₩33.0B | ₩7.80B | ₩1.78B | ₩2.31B | ₩25.5B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| NATURECELL 007390.KS | $1.03B | +17% | -15% | -54% | 72.8× | n/a |
| CHA Biotech 085660.KS | $523M | -52% | +4% | -7% | 1.4× | n/a |
| Mesoblast MSB.AX | $1.49B | -17% | +556% | -43% | 12.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 007390.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.5% | 0.0% | 4th lowest of 21 |
| 6-month return | +17.5% | -2.0% | 4th highest of 21 |
| Distance from 52-week high | -42.0% | -19.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | -14.5% | +2.7% | 2nd lowest of 21 |
| Operating margin | -53.5% | 8.2% | lowest of 20 |
| EV / Sales | 72.8× | 1.5× | most expensive of 21 |
| ROIC minus cost of capital | -20.8 pp | +0.5 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NATURECELL 007390.KS | South Korea | $1.03B | +17% | -15% | -54% | 72.8× | n/a | n/a |
| Lassonde Industries LAS-A.TO | Canada | $1.05B | +9% | -1% | 9% | 0.7× | -12.9% | +8.2% |
| Shenzhen Cereals 000019.SZ | China | $979M | -17% | +1% | 6% | 1.5× | 3.9% | -14.3% |
| A.G. BARR p.l.c BAG.L | United Kingdom | $885M | -2% | +7% | 15% | 1.6× | n/a | n/a |
| Princes PRN.L | United Kingdom | $1.28B | +28% | +30% | 4% | 0.4× | -5.0% | +9.3% |
| LotteChilsung 005300.KS | South Korea | $771M | -13% | 0% | 4% | 0.6× | 0.1% | +12.0% |
| Fevertree Drinks FEVR.L | United Kingdom | $1.39B | +25% | +2% | 9% | 2.9× | 29.2% | +5.2% |
| China Foods 0506.HK | Hong Kong | $1.42B | +14% | +4% | 8% | 0.4× | -16.8% | +4.3% |
| DyDo 2590.T | Japan | $612M | +16% | +3% | 4% | 0.4× | n/a | n/a |
| Nanfang Black Sesame 000716.SZ | China | $554M | -7% | +14% | 3% | 1.8× | 11.0% | -10.1% |
| Nichols NICL.L | United Kingdom | $543M | +19% | +3% | 18% | 1.9× | 1.0% | +8.1% |
| Zhe Jiang Li Zi Yuan Food 605337.SS | China | $501M | -16% | -4% | 12% | 2.9× | n/a | n/a |
| Premium Water 2588.T | Japan | $493M | 0% | +5% | 16% | 1.5× | -10.6% | +7.4% |
| China Resources Beverage (Holdings) 2460.HK | Hong Kong | $2.28B | -9% | -19% | 6% | 1.0× | n/a | n/a |
| Lifedrink 2585.T | Japan | $430M | -2% | +23% | 10% | 1.6× | n/a | n/a |
| SDIC Zhonglu Fruit Juice 600962.SS | China | $2.53B | -16% | +100% | n/a | 3.7× | n/a | n/a |
| Hey-Song 1234.TW | Taiwan | $384M | -7% | -3% | 5% | 1.5× | 12.1% | +0.7% |
| 5100 Xizang Glacier 1115.HK | Hong Kong | $364M | +7% | +67% | 21% | 8.0× | n/a | n/a |
| Hokkaido Coca-Cola Bottling 2573.T | Japan | $336M | -4% | +3% | 3% | 0.8× | 8.5% | +2.8% |
| National Beverage FIZZ | United States | $3.50B | +6% | -2% | 18% | 2.9× | 3.8% | +1.9% |
| Yeo Hiap Seng Y03.SI | Singapore | $259M | -12% | -3% | -7% | 0.5× | n/a | n/a |